Current Environment:

Research & Innovation | Overview

Articles from John G. Meara, MD, DMD, MBA

Articles from Reza Rahbar, DMD, MD, FACS

A new target for lymphoma therapy

Frederick Alt, PhD, and his team discovered that IgH3’RR is also responsible for the over-activation of c-myc that leads to lymphoma. They believe IgH3’RR may be a new target for drugs targeting Burkitt lymphoma, multiple myelomas, and other blood-related cancers that originate in mature B cells. Dec. 10, Nature.